Waltham, MA — Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that under the terms of its collaboration agreement with Isis Pharmaceuticals, the Company will provide Isis with testing kits and will prepare DNA, run genotypes and provide data for SNP genotypes for the IL-1 and LP(a) SNPs for Isis’ Phase 1 clinical study evaluating its novel therapeutic, ISIS-APO(a)-LRx in healthy volunteers with elevated lipoprotein(a), or Lp(a). Lp(a) is an independent risk factor for cardiovascular disease. This Phase I study is the second Isis clinical study to incorporate Interleukin’s genetic test into the trial design to add genetic information at the earliest phases of testing of their new product lines.
Kenneth S. Kornman, DDS, PhD, Chief Executive Officer of Interleukin, stated, “Identifying individuals with elevated oxidized phospholipids, as represented by Lp(a), is important, as such patients are at increased risk for coronary artery atherosclerosis (Tsimikas et al. 2005). However, the linear relationship was only present in individuals who tested positive for our pro-inflammatory IL-1 genetic patterns (Tsimikas et al. 2014). Identification of healthy individuals with elevated Lp(a) along with positive genetic risk factors has the potential to provide health professionals with new information for predictive testing of their patients.
In January 2015, Interleukin announced a collaboration agreement with Isis under which Isis will use Interleukin’s current and newly developed genetic test panels for inflammatory and metabolic diseases to explore genetic factors that may add value in certain clinical trials, such as the Phase I study of ISIS-APO(a)-LRx and the Phase II study with ISIS-APO(a)Rx announced in January.
About Interleukin Genetics
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ lead products include its proprietary PerioPredict® genetic risk panel for periodontal disease and tooth loss susceptibility available through dentists, and the Inherent Health® Weight Management Genetic Test that identifies the most effective diet program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements, including statements related to the potential for the Company’s genetic test to add value in ISIS’ clinical trial and that the identification of healthy individuals with elevated Lp(a) along with positive genetic risk factors has the potential to provide health professionals with new information for predictive testing of their patients. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company’s annual report on Form 10-K for the year ended December 31, 2013 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.